ICAD INC (ICAD) Stock Price, Quote, News and Overview
NASDAQ:ICAD - Nasdaq - US44934S2068 - Common Stock - Currency: USD
ICAD Quote, Performance and Key Statistics
3.91
-0.02 (-0.51%)
The current stock price of ICAD is 3.91 USD. In the past month the price increased by 102.59%. In the past year, price increased by 123.43%.
ICAD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.35 | 39.10B | ||
| DOCS | DOXIMITY INC-CLASS A | 46.48 | 11.16B | ||
| WAY | WAYSTAR HOLDING CORP | 50 | 6.83B | ||
| CERT | CERTARA INC | 23.92 | 1.89B | ||
| SDGR | SCHRODINGER INC | N/A | 1.76B | ||
| PHR | PHREESIA INC | N/A | 1.54B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 12.56 | 1.53B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.29B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.08B | ||
| EVH | EVOLENT HEALTH INC - A | 23.53 | 1.05B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 837.09M | ||
| HSTM | HEALTHSTREAM INC | 42.98 | 826.75M |
Related stock screener links
About ICAD
Company Profile
iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 66 full-time employees. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.
Company Info
ICAD INC
98 Spit Brook Rd Ste 100
Nashua NEW HAMPSHIRE 03062 US
CEO: Michael Klein
Employees: 66
Phone: 16038825200
ICAD INC / ICAD FAQ
What is the stock price of ICAD INC today?
The current stock price of ICAD is 3.91 USD. The price decreased by -0.51% in the last trading session.
What is the ticker symbol for ICAD INC stock?
The exchange symbol of ICAD INC is ICAD and it is listed on the Nasdaq exchange.
On which exchange is ICAD stock listed?
ICAD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ICAD INC stock?
10 analysts have analysed ICAD and the average price target is 3.57 USD. This implies a price decrease of -8.7% is expected in the next year compared to the current price of 3.91. Check the ICAD INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ICAD INC worth?
ICAD INC (ICAD) has a market capitalization of 107.02M USD. This makes ICAD a Micro Cap stock.
How many employees does ICAD INC have?
ICAD INC (ICAD) currently has 66 employees.
What are the support and resistance levels for ICAD INC (ICAD) stock?
ICAD INC (ICAD) has a support level at 1.68. Check the full technical report for a detailed analysis of ICAD support and resistance levels.
Is ICAD INC (ICAD) expected to grow?
The Revenue of ICAD INC (ICAD) is expected to grow by 3.63% in the next year. Check the estimates tab for more information on the ICAD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ICAD INC (ICAD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICAD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICAD, evaluating the profitability, health, valuation and growth aspects
- ICAD INC (ICAD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ICAD INC (ICAD) Sales and EPS estimates to see what analysts future expectations are.
- ICAD INC (ICAD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ICAD INC (ICAD) Insider and Institutional Ownership to learn about the owners and their transactions.
- ICAD INC (ICAD) Stock Chart to make your own analysis
- ICAD INC (ICAD) Latest news and press-releases to stay up to date.
Does ICAD INC (ICAD) stock pay dividends?
ICAD does not pay a dividend.
When does ICAD INC (ICAD) report earnings?
ICAD INC (ICAD) will report earnings on 2025-05-19, before the market open.
What is the Price/Earnings (PE) ratio of ICAD INC (ICAD)?
ICAD INC (ICAD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
What is the Short Interest ratio of ICAD INC (ICAD) stock?
The outstanding short interest for ICAD INC (ICAD) is 1.2% of its float. Check the ownership tab for more information on the ICAD short interest.
ICAD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ICAD. When comparing the yearly performance of all stocks, ICAD is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
ICAD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICAD. While ICAD has a great health rating, there are worries on its profitability.
ICAD Financial Highlights
Over the last trailing twelve months ICAD reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 4.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.96% | ||
| ROE | -19.58% | ||
| Debt/Equity | 0 |
ICAD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to ICAD. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -6.86% and a revenue growth 3.63% for ICAD